Abstract
We have previously shown that the risk of major depression in patients with malignant melanoma undergoing interferon-α (IFN-α) therapy can be reduced by pretreatment with the antidepressant, paroxetine. Using dimensional analyses, the present study assessed the expression and treatment responsiveness of specific clusters of neuropsychiatric symptoms over the first three months of IFN-α therapy.
Forty patients with malignant melanoma eligible for IFN-α treatment were randomly assigned to receive either paroxetine or placebo in a double-blind design. Neuropsychiatric assessments were conducted at regular intervals during the first twelve weeks of IFN-α therapy and included the 21-item Hamilton Depression Rating Scale, the 14-item Hamilton Anxiety Rating Scale and the Neurotoxicity Rating Scale.
Neurovegetative and somatic symptoms including anorexia, fatigue and pain appeared within two weeks of IFN-α therapy in a large proportion of patients. In contrast, symptoms of depressed mood, anxiety and cognitive dysfunction appeared later during IFN-α treatment and more specifically in patients who met DSM-IV criteria for major depression. Symptoms of depression, anxiety, cognitive dysfunction and pain were more responsive, whereas symptoms of fatigue and anorexia were less responsive, to paroxetine treatment. These data demonstrate distinct phenomenology and treatment responsiveness of symptom dimensions induced by IFN-α, and suggest that different mechanisms mediate the various behavioral manifestations of cytokine-induced “sickness behavior.”
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association. (1994): Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association.
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M . (1995): Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286–290
Barkin RL, Fawcett J . (2000): The management challenges of chronic pain: the role of antidepressants. Am J Ther 7: 31–47
Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG . (1991): Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 294: 425–435
Capuron L, Ravaud A, Dantzer R . (2000): Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18: 2143–2151
Carpiniello B, Orru MG, Baita A, Pariante CM, Farci G . (1998): Mania induced by withdrawal of treatment with interferon alfa. Arch Gen Psychiatry 55: 88–89
Castanon N, Bluthe RM, Dantzer R . (2001): Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology 154: 50–60
Chaput Y, De Montigny C, Blier P . (1991): Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5: 219–229
Dantzer R, Bluthe RM, Laye S, Bret-Dibat JL, Parnet P, Kelley KW . (1998): Cytokines and sickness behavior. Ann N Y Acad Sci 840: 586–590
Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL . (1985): Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1: 1166
Folstein MF, Folstein SE, McHugh PR . (1975): “Mini-mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198
Foster CA, Bafaloukos J . (1994): Paroxetine in the treatment of chronic daily headache. Headache 34: 587–589
Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, Luger A . (1993): Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 57: 489–495
Goodnick PJ, Jorge CM . (1999): Treatment of chronic fatigue syndrome with nefazodone. Am J Psychiatry 156: 797–798
Gutterman JU . (1994): Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 91: 1198–1205
Hamilton M . (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62
Holsboer F, Barden N . (1996): Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17: 187–205
Kent S, Bluthe RM, Kelley KW, Dantzer R . (1992): Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13: 24–28
Kent S, Bret-Dibat JL, Kelley KW, Dantzer R . (1996): Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci Biobehav Rev 20: 171–175
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH . (1996): Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17
Koenig HG, George LK, Peterson BL, Pieper CF . (1997): Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 154: 1376–1383
Lacosta S, Merali Z, Anisman H . (1999): Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav Neurosci 113: 1030–1041
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH . (2000): Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296–305
Licinio J, Kling MA, Hauser P . (1998): Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 25 (suppl 1): 30–38
Lynch ME . (2001): Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 26: 30–36
Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S . (1999): Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20: 370–379
Maier W, Buller R, Philipp M, Heuser I . (1988): The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 14: 61–68
Meyers CA, Scheibel RS, Forman AD . (1991): Persistent neurotoxicity of systematically administered interferon-alpha. Neurology 41: 672–676
Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K . (1999): Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 156: 1120
Morrow GR, Hickok JT, Raubertas RF, Flynn PJ, Hynes HE, Banerjee TK, Kirshner JJ, King DK . (2001): Effect of an SSRI antidepressant on fatigue and depression in seven hundred thirty-eight cancer patients treated with chemotherapy: a URCC CCOP study. Proc Am Soc Clin Oncol 20 (Abstr. 1531): 348a
Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH . (2001): Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961–966
Pariante CM, Miller AH . (2001): Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391–404
Ravaud A, Bedane C, Geoffrois L, Lesimple T, Delaunay M . (1999): Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer 80: 1767–1769
Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA . (1987): Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 147: 1577–1580
Schreiber S, Backer MM, Yanai J, Pick CG . (1996): The antinociceptive effect of fluvoxamine. Eur Neuropsychopharmacol 6: 281–284
Schultz M, Muller R, Von zur Muhlen A, Brabant G . (1989): Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1: 1452
Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE . (1999): Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci 65: 1773–1786
Taylor JL, Grossberg SE . (1998): The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 25(suppl 1):23–29
Valentine AD, Meyers CA, Talpaz M . (1995): Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 13: 561–566
Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P . (1998): Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 25(suppl 1):39–47
Vercoulen JH, Swanink CM, Zitman FG, Vreden SG, Hoofs MP, Fennis JF, Galama JM, Van der Meer JW, Bleijenberg G . (1996): Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 347: 858–861
Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IT, Morris JA . (1998): Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 172: 485–490
White PD, Grover SA, Kangro HO, Thomas JM, Amess J, Clare AW . (1995): The validity and reliability of the fatigue syndrome that follows glandular fever. Psychol Med 25: 917–924
Yirmiya R . (1996): Endotoxin produces a depressive-like episode in rats. Brain Res 711: 163–174
Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, Weihe E, Weidenfeld J . (2001): Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 24: 531–544
Acknowledgements
Supported by grants from the National Institute of Mental Health (MH00680 and MH60723), the Centers for Disease Control, Schering-Plough Pharmaceuticals, and Glaxo-SmithKline.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Capuron, L., Gumnick, J., Musselman, D. et al. Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions. Neuropsychopharmacol 26, 643–652 (2002). https://doi.org/10.1016/S0893-133X(01)00407-9
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00407-9
Keywords
This article is cited by
-
The role of polyunsaturated fatty acids in the neurobiology of major depressive disorder and suicide risk
Molecular Psychiatry (2024)
-
Developing symptom clusters: linking inflammatory biomarkers to depressive symptom profiles
Translational Psychiatry (2022)
-
Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers
Translational Psychiatry (2021)
-
Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
Molecular Psychiatry (2021)
-
Toll-like receptor 4-mediated cytokine synthesis and post-stroke depressive symptoms
Translational Psychiatry (2021)
